PURPOSE The aim of the current work was to report the effect of imatinib on pregnancy in patients with chronic myeloid leukemia (CML).
INTRODUCTION
It has been observed that, during pregnancy, the prevalence of leukemia is less than one in 10,000 pregnancies. 1 Today, for patients with chronic myeloid leukemia (CML), imatinib mesylate has become the standard therapy. If a patient wants to get pregnant, it is advisable to plan the pregnancy and to aim for a response as deep as possible, at least a major molecular response (MMR). Therapy should then be interrupted, with a preference for a 3-month washout before conception and for the duration of the pregnancy. Therapy should be resumed immediately after birth; however, if there is an unplanned pregnancy or if the patient is diagnosed while pregnant, the issue is more complicated. Although there have been some instances reported in which patients continued therapy throughout pregnancy with no problems for the baby, it is not recommend to use a tyrosine kinase inhibitor (TKI) at all during pregnancy. 2 In the current study, we report the outcomes of imatinib therapy in pregnant patients or their female partners-for male patients with CML-conceived while receiving imatinib for CML.
METHODS
In this retrospective analysis from a single center in India from January 1998 to December 2014, a total of 2,008 patients with CML were treated at our center. Of 2,008 patients, 5.1% met the inclusion criteria for this study. This study was permitted by our institution review board and written informed consent was obtained from all eligible patients. Data on age, sex, Author affiliations and support information (if applicable) appear at the end of this article.
Accepted on August 20, 2019 and published at ascopubs.org/journal/ jgo on October 4, 2019: DOI https://doi. org/10.1200/JGO. 18 . 00211 symptoms, signs, and laboratory parameters were extracted from the medical record department of our center and entered into Excel (Microsoft, Redmond, WA). From January 1998 to February 2002, patients were treated with non-TKI-based treatments, including hydroxyurea, interferon-alpha, and/or leukapheresis. After US Food and Drug Administration (FDA) approval of imatinib, most patients were treated with this TKI.
Inclusion Criteria
We included pregnant patients and male patients with female partners who conceived while taking imatinib who were diagnosed with Ph chromosome-positive CML (CP or AP or BC) by conventional cytogenetics, fluorescence in situ hybridization (FISH) for BCR-ABL or by reverse transcript quantitative polymerase chain reaction (RT-qPCR) for BCR-ABL.
Exclusion Criteria
No pregnant patients were excluded.
Assessment
At our tertiary care center, any patients with suspected CML underwent assessment, including CBC, renal function test, liver function test, lactate dehyrogenase, serum uric acid, serum electrolytes, abdominal sonography, bone marrow aspiration, and conventional cytogenetics. If marrow cytogenetic assessment failed, then FISH or RT-qPCR was performed from peripheral blood. Immunophenotyping was performed if blast crisis was present.
Treatment
All pregnant patients who were taking imatinib at the time of diagnosis during the first, second, or third trimester of the conception were counseled regarding teratogenicity, toxicity, and safety data of imatinib and advised to stop imatinib and undergo therapeutic abortion if possible and, if at near term, were advised to undergo preterm delivery after consulting with an expert gynecologist. If the patient wanted to continue the pregnancy at her own risk and was not willing to undergo leukapheresis and interferon-alpha therapy, she was allowed to take imatinib at a dose of 400 mg per day. All male patients with CML were allowed to take imatinib at a dose of 400 mg per day.
Leukapheresis is offered in all three trimesters and interferon alpha is advised in second and third trimester. Hydroxyurea 25 mg/kg was continued in pre-imatinib era.
Diagnostic Criteria for Different Phases of CML
Peripheral blood can be used to diagnose CML. Typical indications of CML are an elevated WBC count with left shift, frequently with basophilia, and an enlarged spleen. For proper workup, a bone marrow aspiration along with cytogenic analysis is mandatory, although FISH or polymerase chain reaction for BCR-ABL can be used to confirm the presence of BCR-ABL.
Response Evaluation
We used European LeukemiaNet guidelines to assess the response of imatinib and for additional monitoring of patients. Response was assessed with standardized RT-qPCR and/or cytogenetics at 3, 6, and 12 months. BCR-ABL1 transcript levels of 10% or less at 3 months, less than 1% at 6 months, and 0.1% or less from 12 months onward define optimal response, whereas levels of more than 10% at 6 months and more than 1% from 12 months onward define failure, requiring a deviation from current path of treatment. Similarly, partial cytogenetic response at 3 months and complete cytogenetic response (CCyR) from 6 months onward define optimal response, whereas no cytogenic response (Ph positive . 95%) at 3 months, less than partial cytogenetic response at 6 months, and less than CCyR from 12 months onward define failure.
RESULTS
Clinical characteristics of patients at presentation are as follows: Median age at presentation for males was 36 years (range, 25 to 45 years) and for females was 27 years (range, 21 to 36 years); 55.7% of patients (n = 58) were male and 44.3% (n = 46) were female. We noted common initial clinical symptoms in patients, such as generalized weakness (67.3%), heaviness of the left hypochondriac region (65.3%), abdominal pain (62.5%), fever (54.8%), and bleeding (1%). The hematologic profile of the study population is as follows: Average hemoglobin was 8.4 g/dL (range, 6 to 14 g/dL), WBC per cubic millimeter was 32,000 (range, 4,500 to 120,000/cubic mm), and platelet count per cubic millimeter was 290,000 (range, 19,000 to 940,000/cubic mm). The disease profile at presentation was CML-CP in 79.8% (n = 83), CML-AP in 19.2% (n = 20), and CML-BC in 1% (n = 1) of patients. Distribution of pregnant female patients (n = 46) according to the trimester of the pregnancy are as follows: first trimester, 45% to 6% (n = 21); second trimester, 32.6% (n = 15); and third trimester, 21.7% (n = 10). Of 46 female patients, 21 patients underwent therapeutic abortion ( Table 1) .
Outcomes in Male Patients
Outcomes of full-term pregnancy in female partners of male patients with CML were uneventful and without any congenital malformations to infants.
Outcomes in Female Patients
Of 46 female patients, 25 had full-term pregnancy outcomes. During the pre-imatinib era, of six patients, three were treated with hydroxyurea, interferon alpha (n = 1), and/or therapeutic leukapheresis (n = 2), and all patients had normal full-term deliveries without any complications. Nineteen pregnant patients were receiving imatinib at the time of enrollment and were counseled regarding the safety of the drug and advised to discontinue. Even after proper counseling, 10 of 19 patients continued imatinib until the time of delivery. Of 10 patients, seven had normal full-term delivery, there was one preterm delivery, one with omphalocele, and another infant had craniosynostosis. Of those who discontinued imatinib (n = 9), eight patients had fullterm normal delivery, of which two patients required leukapheresis. One patient expired from multiorgan failure as a result of septic shock during the perinatal period because of postpartum sepsis, which was determined to be unrelated to CML because her hematologic profile and RT-qPCR were normal except neutrophilia with left shift. All patients who continued imatinib even after counseling while pregnant were in CCyR and MMR prepregnancy, during pregnancy, and postpregnancy ( Table 2) .
Observation of Newborns
• Newborns of male patients with CML who are receiving imatinib: All newborns (age range, newborn to 11 years old), toddlers, and children were doing well with normal development of all milestones (gross motor, fine motor, language, cognitive, social skills, vision, and hearing). • Newborns of female patients with CML in the pre-imatinib era: All six newborns (age range, 13 to 22 years old), toddlers, and children were doing well with normal development of all milestones. • Newborns of female patients with CML in the postimatinib era:
• Newborns of female CML patients who discontinued imatinib after proper counseling: All nine newborns (age range, 4 to 8 years old), toddlers, and children were doing well with normal development of all milestones. • Newborns of female patients with CML who continued imatinib after proper counseling: All eight newborns Outcomes were accessible for 125 patients (69%), of which 50% delivered normal infants and 28% underwent optional terminations, three of which followed the identification of abnormalities, and 14% had a miscarriage There were a total of 12 infants in whom abnormalities were identified, three of which had strikingly comparable complex malformations that are obviously a cause for worry
Although most pregnancies exposed to imatinib are likely to have a successful result, there remains a risk that exposure may result in grave fetal malformations Nomura et al 33 2011 9
Of nine patients, four were treated with imatinib when they became pregnant, with treatment being interrupted in the first trimester in three patients and in the second trimester in one During pregnancy, three patients (33.3%) required no chemotherapy after discontinuation of imatinib, and six (66.7%) were treated with interferon (n = 5) and/or hydroxyurea (n = 3).
The mean gestational age at delivery was 37.6 weeks and the mean birth weight was 2,870 g in CML-associated pregnancies Fig 1) , and who are on treatment with imatinib and planning an elective pregnancy or planned pregnancy (Fig 2) . Generally, RT-qPCR increases if the patient is taken off treatment, but this increase does not necessitate the treatment to be intervened. When the patient is taken off treatment, the first measurement should be performed after 2 to 3 three months. However, the frequency of additional monitoring will be decided by the rate at which the full blood count of the patient increases initially and RT-qPCR. Another treatment approach that considers leukemic burden and pregnancy terms may be helpful for avoiding interventions in treatment in the case of favorable situations and takes into account the interests of both the child and mother when treatment initiation becomes necessary. For female patients with CML, this treatment approach can significantly increase the chances of having children. Even so, both the patient and physician should understand the possible risks.
Managing CML at pregnancy with huge leukemic mass is still a complicated task; pregnancy with CML should be thoroughly planned at deep remission. In patients with less than 15 weeks of gestation, TKIs should be stopped and patients should be observed without treatment. After 15 weeks of gestation, if BCR-ABL is less than 1% we can observe without any treatment, and if BCR-ABL is more than 1% we can restart therapy with imatinib, nilotinib, and no dasatinib.
DISCUSSION
The most common malignancies associated with pregnancy are cervical cancer, breast cancer, melanoma, lymphomas, and acute leukemia. 3 CML presents as approximately 10% cases of pregnancy-associated leukemia. CML in pregnancy is not associated with an increase in premature infants, low birth weight, or abortion rates, which were concerns previously. The disease course is akin to that in nonpregnant females. 4 Management options for CML diagnosed in pregnancy are imatinib, hydroxyurea, interferon alfa, and leukapheresis. 5 During the pre-imatinib era, literature has revealed reasonably varied facts regarding hydroxyurea, but not enough to be endorsed by the FDA. 6 Hydroxyurea was used as a cytotoxic agent before the discovery of TKI and has been documented to cause fetal growth restriction, intrauterine death, and craniofacial and spinal defects. 7, 8 Cytotoxic chemotherapy, such as busulphan, is significantly associated with fetal malformations. 9 Interferon alpha works slowly but the FDA has approved interferon alpha as category C during pregnancy. There are several case series that have demonstrated that leukapheresis may be considered a safe procedure in situations when protection of the fetus is preferred, mainly during hyperleukocytosis. 10, 11 As compelling data do not exist at present, use of TKIs and other cytotoxic agents could not be suggested for regular use. Interferon alpha has a higher molecular weight-unable to cross the placenta-and does not inhibit DNA synthesis. Hence, it is considered safe in pregnancy. 7, 12 Imatinib has changed a mortal disease with a median survival of 6 to 7 years into a chronic condition for a large number of patients. Apart from inhibiting the BCR-ABL1 protein, TKIs also reduce stem-cell factor (c-kit), plateletderived growth factor receptors, arg, c-fms, and src-especially by dasatinib-proteins, which are pertinent to implantation, fetal maturation, and gonadal development, at least revealed by animal studies. 5, 13 
Imatinib in Men
There is no increased jeopardy of congenital malformations or increased abortion with usual and higher doses of imatinib. 9, [14] [15] [16] Previous studies have shown that imatinib can potentially hamper postnatal testicular development and sperm capacitation in animal studies. 13, 17 Newer studies have shown that imatinib exposure leads to a significant decline in testosterone levels in adult patients with CML 18, 19 ; however, outcomes of pregnancy in more than 150 patients were uneventful, excluding the malrotation of the intestine and single stillbirth with malformations. 20 An imatinib-treated patient with hyper eosinophilic syndrome developed oligospermia. 21 No special safety measures are relevant for male patients receiving TKIs. 22 
Imatinib in Women
Imatinib use in pregnancy comes under category D according to FDA. Women should be well informed about the impending danger to the fetus if used during pregnancy or if the patient becomes pregnant while taking this drug. It is recommended that female patients follow adequate contraception. With imatinib, the majority of patients achieve deep, long-lasting responses, which is associated with normal life expectancy. Mammalian ovaries express c-kit, c-abl, and platelet-derived growth factor, which are inhibited by TKI, that are imperative in the growth and maturity of oocytes and follicles. [23] [24] [25] When CML is diagnosed in the first trimester, termination of pregnancy is considered harmless for the mother; however, TKIs are associated with fetal malformations if used in the second trimester. Platelet-derived growth factor A inhibition of imatinib resulted in teratogenicity in mice. 26 Distinguishing congenital abnormalities have occurred after the administration of imatinib in early pregnancy. These include exomphalos, omphaloceles, pulmonary hypoplasia, duplex kidneys, renal agenesis, skeletal malformations (craniosynostosis, shoulder anomaly, and scoliosis), and spontaneous abortion. 22 The incidence of exomphalos is approximately 100-fold greater than predictable. Once pregnancy has been documented, if the patient is receiving imatinib it should be stopped. Close monitoring of fetal growth, especially a nuchal scan, should be performed for fetal anomalies. No trial has demonstrated cumulative toxicity of imatinib and fetal malformations. 3 Cole et al 27 studied the cases of 215 women who became pregnant while taking imatinib until 2009. Of 215 women, 171 sustained their pregnancy to term-62 of them had unknown outcomes, whereas 109 pregnancies had known outcomes: 33% (n = 36) had complications, such as spontaneous abortion (n = 24), stillbirth (n = 1), malformations (n = 9), and low birth weight (n = 2). 27 Imatinib does not have any effect on folliculogenesis or spermatogenesis. 28 Until now, the number of cases of pregnant women with CML reported in the literature is more than 200; however, with the exception of imatinib, there are no data available on the use of targeted agents nor various landmark studies of imatinib in pregnant patients with CML (Table 1) .
Second-Generation TKI During Pregnancy 20, 29 (Table 3) Nilotinib for men: Little has been reported regarding conception during nilotinib treatment. 30 Nilotinib for women: As for men, little has been reported for women who become pregnant while being treated with nilotinib. One patient at the 3-month ultrasound showed a large omphalocele, which resulted in the pregnancy interruption, and another patient's fetus was exposed to nilotinib for 5 weeks before stopping therapy and pregnancy was unremarkable, with the delivery of a healthy girl. Dasatinib for men: Cortes et al 30a studied the effects of dasatinib on pregnant partners of nine male patients who conceived children while receiving dasatinib. Of these patients, one mother experienced preeclampsia but eventually delivered a healthy baby at 37 weeks, free of any birth defects or neonatal complications. 30, 31 Dasatinib for women: To study the effect of dasatinib on pregnant women, 13 pregnant patients were observed. Of these patients, only one normal newborn was delivered; one patient gave birth to a premature newborn, four women had to undergo induced abortions, another two had spontaneous abortions, and five women were pregnant at last reported follow-up. In conclusion, temporarily discontinuing TKIs nilotinib and dasatinib, then observing or intervening with interferon alpha and/or leukapheresis, can be considered to be the safest and thus the best potential therapeutic options for the management of CML in pregnancy. 31 Other TKIs: No conceptions/pregnancies have been reported while receiving ponatinib.
Breast Feeding
Imatinib and its active metabolite are excreted into human milk.
Future Perspectives
Some stopping imatinib studies (TWISTER [A phase II study to determine relapse-free interval after withdrawal of imatinib therapy in adult patients with chronic phase chronic myeloid leukaemia in stable complete molecular remission] and STIM [Stop Imatinib] trials) have demonstrated that even after discontinuing imatinib and attaining complete molecular response for 2 years, nearly 40% of patients maintain a deep response with undetectable BCR-ABL1 transcripts. 30, 31 On the basis of existing data, female patients with CML who have a desire become pregnant should be advised to wait until persistent MMR is achieved for a minimum of 2 years with monitoring of CBC and RT-qPCR. For future assisted conception in patients who at least achieve complete hematologic response and who plan for future pregnancy, it is advised to collect oocytes. Start in vitro fertilization drugs 7 days after stopping TKI and resume TKI after the oocytes collection ( Table 4 ).
Impact of Imatinib and Other 2G-TKIs on Pregnancy in Patients With CML
Physiologic changes, which also include changes in hematologic parameters accompanying pregnancy, may 
CML First Trimester Outcome
Dasatinib (n = 4) n = 1 38 Fetal hydrops and cytopenias n = 1 (5/40 weeks) 39 Normal pregnancy, induction of labor n = 1 (4/40 weeks) 40 Normal pregnancy, LSCS at 33 weeks n = 1 (6/40 weeks) 41 Normal pregnancy, SVD at 37/40 weeks complicate the diagnosis of CML during pregnancy as they may mask the symptoms.
As the prothrombotic proteins and hemostatic factors increase physiologically, and the venous blood flow is obstructed physically, the prothrombotic potential of a normal pregnancy is recognized. Hence, it is clear that thrombosis can be considered to be the most common cause of maternal morbidity. In the case of myeloproliferative diseases, this may be compounded where there is an associated increase in blood platelet count. 5, 13 All TKIs have similar class effects as they inhibit BCR-ABL1. TKIs also have a lot of off-target effects as a result of the inhibition of c-kit, platelet-derived growth factor receptors, arg, and c-fms. Furthermore, it should be noted that one of the 2G-TKIs, dasatinib, also inhibits src and related proteins, which are relevant to gonadal development, embryonic implantation, and fetal maturation. 5, 13 Less experience has been reported with 2G-TKIs [36] [37] [38] [39] [40] [41] [42] (Table 3 ; bosutinib, dasatinib, nilotinib, and ponatinib) in pregnancy. Dual BCR-ABL/src kinase inhibitor dasatinib crosses the placenta and results in considerable levels of fetal plasma. It has been reported that, in the first trimester, dasatinib causes fetal hydrops and severe fetal bicytopenia; however, there have been reports of some pregnancies as well.
In conclusion, the management of CML during pregnancy poses a therapeutic dilemma because of the potential teratogenic effect of therapy and requires the contemplation of both maternal and fetal life. Imatinib use during pregnancy is a double-edged sword, because discontinuation of the drug is associated with a loss of cytogenetic and molecular response, as well as consequences of the disease and, if No potential conflicts of interest were reported.
